SEC Form 4 · accession 0001209191-16-141001
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Luis Borges
Officer — SVP, Research
Period of report
Sep 8, 2016
Accepted (ET)
Sep 12, 2016 · 8:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 8, 2016 | A | 5,000 | $0.00 | A | 71,622 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $49.54 | Sep 8, 2016 | A | 25,000 | A | — | Sep 8, 2026 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of September 1, 2017, 2018 and 2019.
- F2One forty-eighth (1/48th) of the shares underlying the option will vest monthly beginning on October 8, 2016.